Business
Covalon Announces Two New Board Members Following Annual Meeting
MISSISSAUGA, ON , June 16, 2014 /CNW/ - Covalon Technologies Ltd. (the "Company" or ...
About this update from Covalon Technologies Ltd.
[{"type":"text","content":"\n\nMISSISSAUGA, ON, June 16, 2014 /CNW/ - Covalon Technologies Ltd. (the \"Company\" or \"Covalon\") (TSXV: COV), an advanced medical technologies company, is delighted to announce the election of The Honourable Elinor Caplan and Dr. Ian Brindle to the Company's Board of Directors at its annual shareholders meeting.\n\nHon. Elinor Caplan is the Chief Executive Officer of Canada Strategies Inc. She served as former Health Minister and Chair of Management Board for the Province of Ontario and has served as Minister of Citizenship and Immigration as well as Minister of National Revenue in the Cabinet of former Prime Minister, Rt. Hon. Jean Chrétien. Ms. Caplan has served on numerous boards and advisory groups in Canada and internationally and is the co-author of the book, From Innovation to Transformation.\n\nDr. Ian Brindle is the former Vice President of Research and Dean of Chemistry of Brock University.  Dr. Brindle is a professor of Chemistry, holds a Chancellor's Chair in Research Excellence, is a fellow of the Royal Society of Chemistry (UK) and is author of more than 70 publications in analytical chemistry. The University of Manchester awarded Dr. Brindle the degree of Doctor of Science for belonging to that group of scientists who \"have distinguished themselves as authorities in the field by their substantial and original contributions to the advancement of knowledge.\" \n\n\"We are honoured to have Hon. Elinor Caplan and Dr. Ian Brindle join Covalon's Board of Directors,\" said Abe Schwartz, Chairman of the Board.  \"I have had the good fortune to know Elinor and Ian for a number of years and am certain that their broad experience, judgement and enthusiasm will result in a meaningful contribution to Covalon's Board. Elinor and Ian are joining Covalon at a time when the Company has made significant advances in its financial position and is building on these positive financial results with the introduction of new products and the securing of new licensing and distribution relationships for the benefit of its clients, shareholders and staff.\"    \n\nThe Company also announced Board approval of the granting of an aggregate of 102,500 options, vesting annually over three years, at an exercise price of $2.00 to be exercised within five years to Covalon's six independent Board Directors and ...